{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cervero-Garcia P"],"funding":["Blood Cancer UK"],"pagination":["vdag001"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12932952"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["<h4>Background</h4>TAT-Cx43<sub>266-283</sub> is a novel Src inhibitor, which has shown noteworthy antitumor effects in preclinical models of glioblastoma. Because Src plays a pivotal role in several tumor types, including lung cancer brain metastasis derived from non-small cell lung cancer (NSCLC) cells, we investigated the effect of TAT-Cx43<sub>266-283</sub> in NSCLC-derived brain metastasis, a disease of unmet clinical need.<h4>Methods</h4>The effect of TAT-Cx43<sub>266-283</sub> was studied in Lewis Lung Carcinoma (LLC), LSZ4, A549, and H441 NSCLC cells. The non-adherent stem-like LLC cells (LLC-CSCs) were intracranially implanted in immunocompetent mice to study the effect of TAT-Cx43<sub>266-283</sub>  <i>in vivo</i>. Phosphoproteomic analysis was employed to identify signaling path"],"journal":["Neuro-oncology advances"],"pubmed_title":["The Src inhibitor peptide TAT-Cx43&lt;sub&gt;266-283&lt;/sub&gt; improves survival in an intracranial murine model of lung cancer brain metastasis."],"pmcid":["PMC12932952"],"funding_grant_id":["20008"],"pubmed_authors":["Hijazi M","Rodrigues-Teixeira T","Alvarez-Vazquez A","Alonso-Amador JJ","Ollauri-Ibanez C","Martin-Guerrero SM","Cutillas PR","Casado P","Garcia-Guerrero L","Shields T","Flores-Hernandez R","Talaveron R","Tabernero A","Rajeeve V","Cervero-Garcia P","Jimenez-Madrona E","Paniagua-Sancho M","Jaraiz-Rodriguez M","Gonzalez-Sanchez R","Garcia-Vicente L"],"additional_accession":[]},"is_claimable":false,"name":"The Src inhibitor peptide TAT-Cx43&lt;sub&gt;266-283&lt;/sub&gt; improves survival in an intracranial murine model of lung cancer brain metastasis.","description":"<h4>Background</h4>TAT-Cx43<sub>266-283</sub> is a novel Src inhibitor, which has shown noteworthy antitumor effects in preclinical models of glioblastoma. Because Src plays a pivotal role in several tumor types, including lung cancer brain metastasis derived from non-small cell lung cancer (NSCLC) cells, we investigated the effect of TAT-Cx43<sub>266-283</sub> in NSCLC-derived brain metastasis, a disease of unmet clinical need.<h4>Methods</h4>The effect of TAT-Cx43<sub>266-283</sub> was studied in Lewis Lung Carcinoma (LLC), LSZ4, A549, and H441 NSCLC cells. The non-adherent stem-like LLC cells (LLC-CSCs) were intracranially implanted in immunocompetent mice to study the effect of TAT-Cx43<sub>266-283</sub>  <i>in vivo</i>. Phosphoproteomic analysis was employed to identify signaling path","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan-Dec","modification":"2026-07-14T09:22:02.553Z","creation":"2026-07-14T03:04:15.919Z"},"accession":"S-EPMC12932952","cross_references":{"pubmed":["41756757"],"doi":["10.1093/noajnl/vdag001"]}}